



HAL
open science

Impact of sex and APOE- ϵ 4 genotype on patterns of regional brain atrophy in Alzheimer's Disease and healthy ageing

Benoît Sauty, Stanley Durrleman

► **To cite this version:**

Benoît Sauty, Stanley Durrleman. Impact of sex and APOE- ϵ 4 genotype on patterns of regional brain atrophy in Alzheimer's Disease and healthy ageing. 2023. hal-03778801v3

HAL Id: hal-03778801

<https://inria.hal.science/hal-03778801v3>

Preprint submitted on 8 Feb 2023 (v3), last revised 5 Jun 2023 (v4)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Impact of sex and APOE- ϵ 4 genotype on patterns of regional brain atrophy in Alzheimer's Disease and healthy aging.

Benoît Sauty^{a,*}, Stanley Durrleman^a, for the Alzheimer's Disease Neuroimaging Initiative¹

^aSorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France

Abstract

Alzheimer's Disease (AD) is a heterogeneous disease that disproportionately affects women and people with the APOE- ϵ 4 susceptibility gene. We aim to describe the not-well-understood influence of both risk factors on the dynamics of brain atrophy in AD and healthy aging. Regional cortical thinning and brain atrophy were modeled over time using non-linear mixed-effect models and the FreeSurfer software. Covariance analysis was used to disentangle the effect of sex and APOE genotype on the regional onset age and pace of atrophy, while correcting for educational level. A map of the regions most affected by neurodegeneration is provided. Results were confirmed on gray matter density data from the SPM software. Women experience faster atrophic rates in the temporal, frontal, parietal lobes and limbic system and earlier onset in the amygdalas, but slightly later onset in the postcentral and cingulate gyri as well as all regions of the basal ganglia and thalamus. APOE- ϵ 4 genotypes leads to earlier and faster atrophy in the temporal, frontal, parietal lobes and limbic system in AD patients, but not in healthy patients. Higher education was found to slightly delay atrophy in healthy patients, but not for AD patients. A cohort of amyloid positive patients with MCI showed a similar impact of sex as in the healthy cohort, while APOE- ϵ 4 showed similar associations as in the AD cohort. Female sex is as strong a risk factor for AD as APOE- ϵ 4 genotype regarding neurodegeneration. Women experience a sharper atrophy in the later stages of the disease although not a significantly earlier onset. These findings may have important implications for the development of targeted intervention.

Keywords:

Alzheimer's Disease, Longitudinal studies, Brain atrophy, Genetic covariates, Sexual dimorphism, Aging

1. Introduction

Alzheimer's Disease (AD) is a neurodegenerative pathology that accounts for about 70% of the more than 55 millions dementia cases worldwide [1]. A silent phase, referred to as prodromal phase, shows accumulation of structural alterations in the brain without specific symptoms, eventually leading to a progressive cognitive decline that translates into a loss of the patient's autonomy for daily tasks, with impaired mnemonic, visuospatial and communicative functions as well as unusual behaviors such as paranoia and aggressiveness. For people under the age of 75, the incidence of AD has been estimated below 1.0%, while it reaches 8.4% [2, 3] for patients over 85, making older age the most important risk factor of the disease. Other risk factors have been identified with certainty and are briefly presented below.

The second most important risk factor is often said to be the presence of hereditary gene mutations [4]. More precisely, the inheritance of AD can be of two types. On one hand, rare autosomal dominant mutations in APP, PSEN1, and PSEN2, that encode amyloid precursors and presenilin proteins, leading to early-onset (<60 years old) familial AD, which accounts for roughly 5% of cases [4], and are often dismissed from studies on risk factors because of their low prevalence and understood causality. On the other hand, frequent gene polymorphisms, such as the ϵ 4 and ϵ 2 variants of the APOE gene, can influence susceptibility for roughly 50% of the common late-onset AD [4]. Genome wide association studies also identified a handful of other loci as potential risk factors, but thus far, the only gene variant considered to be an established risk factor for late onset AD is the APOE- ϵ 4 allele [5, 6, 1]. The APOE gene provides the blueprint for the apolipoprotein E that transports cholesterol in the bloodstream and helps bind A β to cerebrospinal fluid, effectively clearing the brain of

*Corresponding author: Institut du cerveau, 47 bd de l'Hôpital, 75013 Paris, France, Tel.: +33631040386; e-mail: benoit.sauty-de-chalon@inria.fr

¹Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators is available at <http://tinyurl.com/ADNI-main>.

18 excess $A\beta$. The presence of $\epsilon 4$ allele hinders $A\beta$ clearance and leads to reduced neuronal injury response [7], and in turns
19 correlate with higher AD risks.

20 The other genetic factor that is known to impact AD risk rates is the sex of patients. Two thirds of AD patients are
21 women [1] and their cognitive decline is faster than for men [8]. By contrast, healthy aging tends to display delayed
22 cognitive decline and structural alterations for women. [9] review conflicting studies on the topic of incidence rates and
23 reach the conclusion that before the age of 75, no significant difference in incidence rates is detected, while incidence
24 rates get significantly higher for women than for men after that inflexion point. The longer longevity of women has long
25 been thought to be the sole cause for this discrepancy. However, the loss of the protective effects of estrogens during
26 menopause, demonstrated in vitro and in vivo [10, 11], has also been suggested as a cause. Evidence also highlight a
27 faster loss of autonomy but a longer lifespan after diagnosis for women [12]. These facts raise the question of a sexual
28 dimorphism of AD. A precise understanding of the distinct patterns of structural and functional brain alterations over time
29 is still lacking. Accurate descriptions of those patterns could help to implement better practices to care for both men and
30 women. Besides, women are still underrepresented in clinical trials [13] and only 15% of trials report results stratified by
31 sex [14], although this proportion increases in more recent studies. As suggested in [15], several gendered factors other
32 than sex can also mediate the observed associations, although data is rarely available in large scales datasets.

33 Another often-mentioned risk factor is the education level. According to the cognitive reserve hypothesis, having more
34 years of education increases the connections between neurons and enables the brain to compensate for the early changes of
35 Alzheimer’s by using alternate routes of neuron-to-neuron communication to complete a cognitive task [16, 17]. Women
36 are believed to benefit even more from higher education than men, albeit receiving less education [18]. [19] confirm that
37 education is an indicator of cognitive reserve, but that the protective effects on cognition are depleted as neurodegenera-
38 tion progresses.

39
40 Building on the observation that the influence of sex on the progression of AD is not well understood, and that
41 APOE- $\epsilon 4$ status is the strongest known genetic variant associated with AD, this work aims to describe the disentangled
42 contributions of both those genetic factors on patterns of structural brain alterations, while accounting for biases due to
43 varying education level. Such alterations, that are visible through MRI scans, reveal neurodegeneration occurring before
44 the onset of the cognitive symptoms, and are thus crucial to understanding the early stages of the disease and for the design
45 of drug trials. Leveraging the information from repeated measurements of cortical thicknesses and volumes of subcortical
46 regions allows to describe each patient’s atrophic dynamics and compare across populations. Our goal is thus to provide
47 a map of the brain regions that show significant correlation between sex or APOE- $\epsilon 4$ status and onset age and pace of
48 regional atrophy. We provide this analysis for AD diagnosed and cognitively normal patients in order to emphasize the
49 specificities of Alzheimer’s progression.

50 *1.1. Related work*

51 *Cross-sectional studies.* Over the course of AD progression, the link between cognitive decline and various covariates
52 such as BMI [18], cardiac pathologies, APOE- $\epsilon 4$ genotype [20, 21, 22, 23] and sex have been explored, highlighting a
53 higher impact of comorbidities and APOE- $\epsilon 4$ genotype for women on the severity of the disease symptoms. [24] and
54 [25] review the state of knowledge about the differences across sexes in AD clinical manifestations, biomarkers patterns
55 and risk factors.

56 On the other hand, healthy aging displays comparatively more spared alteration profiles for women compared to men,
57 for both brain atrophy and cognitive decline. Seminal works dating back to the beginning of in-vivo imaging modalities
58 report higher size decreases in men for average brain [26] and frontal and temporal lobes [27]. Many studies have since
59 provided more insights into the differences between sexes for cognitive decline and link with comorbidities [28, 29],
60 exhibiting opposite correlation than in Alzheimer’s studies. [30] exhibit associations between male sex, worse memory
61 and higher hippocampal atrophy.

62 *Longitudinal studies.* The collection of repeated measurements of neuroimaging data and clinical assessment allows
63 a finer understanding of pathological pathways. Notorious modeling approaches include event-based models [31, 32],

64 Gaussian-Process models [33, 34], Deep Learning methods [35, 36] and mixed-effects models. Application of such lon-
65 gitudinal models are frequent for the assessment of cognitive decline [37, 38, 39, 40, 31, 41, 42, 43] but less used for
66 imaging features. [44] advocate the use of linear mixed-effects models (LME) for progression models of neuroimaging
67 data and apply LME to a mesh of control points of cortical thickness in a mass-univariate setting in [45]. [46] correlate
68 these progression models with diagnosis in order to exhibit regions of the cortex that are most representative of the cog-
69 nitive state of patients. Other studies also apply progression models to a few ROIs of the brain [47, 48, 49] in order to
70 display the regions that correlate most with diagnosis. Applying this kind of modeling to a study of sex differences, [50]
71 confirm that atrophy rates are higher for female than male patients and they decrease with age, while [51, 52] explain
72 that brain volumes and cortical thicknesses are consistently smaller for cognitively normal males after accounting for age,
73 and that the differences get smaller as cohorts are chosen at a more advanced state of cognitive decline, until they get
74 indistinguishable for confirmed AD patients, with a sharper decline for women. Those study do not take into account
75 important covariates such as APOE status and educational level, and do not disentangle the age of onset and the pace of
76 atrophy. Many studies report the impact of APOE polymorphisms on brain atrophy for AD progression and link $\epsilon 4$ with
77 faster cortical thinning [53, 54] and hippocampal atrophy [55, 56], with increasing effects as patients get older [57].
78

79 1.2. Contributions

80 Overall, many studies explored the differences between men and women regarding AD progression and healthy brain
81 aging, as well as the influence of APOE polymorphisms. However, many of them rely on cross-sectional data that miss
82 important information about the progression of the disease. Longitudinal tools have been proposed to leverage such in-
83 formation, and have been successfully applied to biomarkers for disease progression models. However, these studies have
84 either focused on the patterns of cognitive decline, or on a chosen set of ROIs to assess structural alterations, thus not
85 providing a detailed map of the differences across the brain. Some longitudinal studies have proposed analysis of cortical
86 thinning or brain atrophy with a high spatial resolution, however the focus has always been put on finding regions that
87 correlate best with diagnosis in order to obtain valuable information about the brain alterations most specific to AD. To
88 the best of our knowledge, no study has yet provided a quantitative comparison between male and female patterns of
89 structural alterations over time, while accounting for APOE- $\epsilon 4$ genotype and education level, in order to provide a map of
90 the brain regions that showcase distinct age-related alterations profiles. Besides, former works usually focus on the impact
91 of one single factor, while only a joint analysis of both the genetic factors allows to isolate the contributions from each one.
92

93 In this context, it seems relevant to further explore the differences between men and women regarding the onset
94 and pace of alterations of the brain in both normal and AD progression, with a high degree of spatial resolution, while
95 accounting for APOE- $\epsilon 4$ genotype and education level. Longitudinal studies allow to leverage information about the
96 progression over time, while mixed-effect models allow for an interpretable modeling of each feature's trajectory across
97 time. To sum up our contributions :

- 98 • We model regional cortical thinning and brain atrophy using non-linear mixed-effect models, and propose a formu-
99 lation that disentangles the onset age and the pace of atrophy,
- 100 • for each region, we proceed to a multivariate regression for the individual parameters with regard to female sex,
101 APOE- $\epsilon 4$ allele count and education level, in order to isolate the effect of each factor,
- 102 • we obtain a brain map of p -values that assess how significantly each factor influences the patterns of atrophy over
103 time, when corrected for the other covariates,
- 104 • we display the regions that differ the most regarding onset age and pace of structural atrophy for the chosen covari-
105 ate, for both healthy and AD progression.

106 This statistical pipeline addresses the lack of understanding of the influence of sex and APOE on structural brain
107 alterations, and disentangles the joint effects of the multiple risk factors.

108 2. Material and Methods

109 *Data sets.* We performed the analysis on publicly available data from all waves (GO,1,2,3) of the Alzheimer’s Disease
 110 Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu), as it provides repeated MRI scans for both cognitively
 111 normal elderlies and AD patients. The ADNI was launched in 2003 as a public-private partnership and its primary goal
 112 has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological
 113 markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive
 114 impairment (MCI) and early Alzheimer’s disease (AD). All scans are quality-checked by trained anatomists. We selected
 115 all patients with at least 2 visits with a MRI scan and selected three cohorts : an AD cohort with patients with at least
 116 one confirmed AD diagnosis, an healthy cohort with patients who are diagnosed cognitively normal at every visit and an
 117 intermediate cohort of amyloid positive patients (see [58] for the chosen cutoffs) with at least one MCI diagnosis but no
 118 AD conversion. Patients with inconsistent AD diagnosis that revert to CN or MCI (107 patients) and amyloid negative
 119 patients (50 patients) are removed from the pathological cohort. Table 1 reports the demographics for the selected ADNI
 120 patients. The AD cohort is composed mostly of late-onset AD (566 patients) but also features a few early-onset cases (24
 121 patients).

	AD cohort		A β + MCI cohort		Healthy cohort	
	Male	Female	Male	Female	Male	Female
Patients (N)	329	261	262	176	210	264
Visits (N_{scan})	1,447	1,092	1,164	794	1,063	1,169
Total follow-up (y)	3.7 \pm 2.9	3.4 \pm 3.0	4.5 \pm 3.4	4.6 \pm 3.3	4.6 \pm 3.3	4.1 \pm 3.0
Age at baseline	75.0 \pm 7.1	73.6 \pm 7.7	75.4 \pm 7.5	71.5 \pm 7.8	74.0 \pm 6.1	72.7 \pm 6.0
Education (y)	16.1 \pm 2.8	14.7 \pm 2.6	16.4 \pm 2.8	15.5 \pm 2.7	17.2 \pm 2.4	16.1 \pm 2.8
APOE- ϵ 4 (2/1/0)	69/163/97	44/133/84	32/99/121	24/71/81	5/51/154	7/75/182
MMSE	24.0 \pm 4.0	23.2 \pm 4.6	27.7 \pm 2.0	28.2 \pm 2.1	29.0 \pm 1.2	29.2 \pm 1.1
ADAS-Cog13	26.5 \pm 10.6	29.2 \pm 11.8	15.3 \pm 6.9	12.6 \pm 6.7	10.0 \pm 4.6	8.3 \pm 4.3

Table 1: Demographics for cohorts selected from ADNI. Numeric fields are in the form mean \pm standard deviation. (y) is years. (2/1/0) refers to the amount of APOE- ϵ 4 alleles. Cognitive scores are for all visits (not just baseline).

122 *Data processing.* These results have been obtained using the t1-freesurfer pipeline of Clinica [59]. This pipeline is a
 123 wrapper of different tools of the FreeSurfer (v6.0) software (<http://surfer.nmr.mgh.harvard.edu/>) [60]. This pro-
 124 cessing includes segmentation of subcortical structures (corpus callosum, ventral Diencephalon, choroid plexus, acum-
 125 bens area, amygdalas, hippocampi, caudate nuclei, putamen, pallidum and thalamus), extraction of cortical surfaces using
 126 the ”recon-all” pipeline, spatial normalization onto the FreeSurfer surface template (FsAverage) and cortical thickness
 127 estimation with respect to the 148 gyral and sulcal structures defined by the Destrieux atlas [61]. The subcortical vol-
 128 umes are normalized by intracranial volumes to account for the size of the head. Late releases of FreeSurfer have been
 129 demonstrated to yield similar atrophic rates to those obtained by manual segmentation for AD patients [62, 63].

130 In order to validate our findings on another modality, we extract gray matter density maps from the same t1-MRI
 131 data from ADNI. These features are obtained using the t1-volume pipeline of Clinica [59]. This pipeline is a wrapper of
 132 the Segmentation, Run Dartel (using a ADNI-based template) and Normalise to MNI Space routines implemented in the
 133 SPM12 software and yields a map of the average gray matter densities in each anatomical region defined in the AAL2
 134 atlas [64], which splits the brain into 80 gyri and sulci for the cortex and 14 subcortical regions. It displays a similar
 135 granularity to the Destrieux atlas and allows comparison. Gray matter density is fundamentally different from cortical
 136 thicknesses and regional volumes, and could potentially exhibit different progression patterns, especially since it is well
 137 documented that women have on average more gray matter and less white matter than men after correcting for brain size,
 138 in most of the brain [65, 66, 67].

139 MRI images from ADNI are acquired with either 1.5T (3440 samples) or 3T (3289 samples) scanners. As noted
 140 in [68], Freesurfer outputs on 3T images are significantly thicker than for 1.5T images, which can hurt longitudinal

141 modeling and bias population-level comparisons. As is common in longitudinal studies, we proceed to bias correction
 142 through histogram matching within each diagnosis group for each extracted feature.

143 *Longitudinal modeling.* Mixed-effects models describe each patient’s progression over time as a small variation – the
 144 random effects of the model – around the average population trajectory – the fixed effects of the model. This study
 145 focuses on univariate models, that are calibrated on the repeated measurements for one region of the cortex or subcortical
 146 structure at a time. Linear mixed-effects models are widely used for longitudinal modeling and assume that features
 147 evolve according to straight lines over time. Each patient is thus characterised by a slope and an intercept. The slope
 148 can be interpreted as the pace of decline of a patient for the given feature, but the intercept is less meaningful. In that
 149 setting, we choose to parametrize the inter-subjects variability as the combined effects of an individual onset age, and a
 150 pace of decline as suggested in [41]. The onset age can be understood as a horizontal intercept and describes the age at
 151 which a patient crosses the population-average-value threshold, and the pace of decline as the slope. Both these temporal
 152 parameters allow to align all patients on a common progression timeline. Namely, given a family of feature observations
 153 $\{y_{i,j}\}$ at times $\{t_{i,j}\}$ for $1 \leq i \leq N$ indexes the N patients and $1 \leq j \leq N_i$ indexes the N_i visits of patient i , we resort to the
 154 mixed-effect generative model

$$y_{i,j} = f\left(e^{\xi_i}(t_{i,j} - \tau_i) + t_0\right) + \varepsilon_{i,j}$$

155 where e^{ξ_i} and τ_i , respectively the *progression pace* and *onset age* of patient i are called the individual parameters that
 156 provide an affine time warp to account for the variability in pace and onset of decline between patients. These individual
 157 parameters form the random effects of the model. We choose the Gaussian priors for the noise $\varepsilon_{i,j} \sim \mathcal{N}(0, \sigma_\varepsilon^2)$ and random
 158 effects $\tau_i \sim \mathcal{N}(t_0, \sigma_\tau^2)$ and $\xi_i \sim \mathcal{N}(0, \sigma_\xi^2)$. In a linear mixed-effects framework, f is an affine function $t \mapsto p_0 + v_0 * (t - t_0)$,
 159 while for non-linear mixed-effects it is usually chosen to be the logistic function $t \mapsto \left(1 + \left(\frac{1}{p_0}\right) \exp\left(\frac{-v_0 t}{p_0(1-p_0)}\right)\right)^{-1}$. The
 160 parameters p_0 , v_0 and t_0 are respectively a reference *position*, *velocity* and *time* and describe the average trajectory.
 161 Together with the variances $\sigma_\varepsilon, \sigma_\tau, \sigma_\xi$, they form the fixed-effects of the model.

162 In practice, logistic regression is one of the most popular shape of trajectory, so all features should be normalized to
 163 the range $[0, 1]$. We thus discard outliers using the so-called three sigma rule and add a min-max normalization within
 164 each cohort, providing realistic asymptotes. Since cortical thicknesses and brain volumes decrease over time, we flip data
 165 around $.5$, using the rotation $x \mapsto 1 - x$, in order to ensure increasingness, which is required for logistic modeling.




Figure 1: Illustration of logistic (first row) and linear (second row) mixed-effects models. Blue curve is the average trajectory (parametrized by t_0 , p_0 and v_0) and red and green curves illustrate the effect of progression pace ($\alpha = e^{\xi}$) and onset age (τ), which allow to match individual measurements (isolated dots) to a continuous trajectory.

166 *Calibration of the model.* These longitudinal statistical models are part of a family of geometric models that have been
 167 studied in [69] and [70]. We can proceed to a Maximum a Posteriori estimation of both random and fixed effects with
 168 the MCMC-SAEM procedure in which the estimation step of an Expectation-Maximization algorithm is replaced by a
 169 stochastic approximation. See [71] and [72] for details on this procedure, description of the complete likelihood and proof
 170 of convergence and stability. One model is calibrated on each of the three cohorts. All analysis is done using the Leaspy
 171 software.

172 *Logistic versus linear regression.* As mentioned above, the choice of f in the mixed-effect formulation should reflect the
173 average progression of the feature. A few methods exist to learn the exact shape of the progression profile [73, 74] but
174 add a strong computational burden. We compared the two most widespread available shapes, namely linear and logistic
175 curves, in order to assess the stability of convergence as well as the estimated noise of the longitudinal fit. The logistic
176 curve marginally surpassed the linear curve for both these criteria.

177 *Goodness of fit.* In order to ensure that the longitudinal models accurately describe the atrophy of each feature, we
178 compare the distributions of reconstruction errors (the differences between the predicted values of the models at the time
179 of each visit and the actual measurements) for the three cohorts to the distribution of measurements noise. Imaging data are
180 indeed subject to variations in the experimental conditions and in the processing pipeline. In order to evaluate this noise,
181 some visits are acquired twice within a few hours. For ADNI, we dispose of 1604 duplicate images from 285 different
182 patients. We provide boxplots that display the empirical distributions of test/re-test errors and of the reconstruction errors
183 for the three cohorts in supplementary materials. Distributions largely overlap, and reconstruction errors fall close to the
184 measurements uncertainty, which hints that our models could not be improved without overfitting. Additionally, it is
185 important to note that the reconstruction errors are not biased regarding sex, APOE status, education level, ADNI phases
186 nor field strength.

187 *Statistical analysis.* Once the univariate models are calibrated, we have a family of patient-wise onset ages and progres-
188 sion paces for each feature. We can thus proceed to statistical testing of the differences between subgroups. To do so,
189 we perform covariance analysis using ordinary least squares to regress the individual parameters with regard to female
190 sex, number of APOE- ϵ 4 alleles and education level of each patient. This evaluates the impact of each covariate after
191 correcting for the other ones, and also the significance of the corresponding association. Since we are in a multiple testing
192 setting, we use False Discovery Rate (FDR) [75] to obtain a map of corrected p -values that assess how certain it is that
193 the chosen covariate influences the onset or pace of atrophy for each region. Given the high number of statistical tests
194 (one for each of the 148 regions of the Destrieux atlas), a more stringent correction method such as Family-Wise Error
195 Rates would be unsuitable as it would discard significant correlations. Absolute pairwise-correlations between covariates
196 are .02 for APOE/sex, .05 for APOE/education and .18 for sex/education, which means that regressing with regards to the
197 education level might mitigate the strength of the observed sexual dimorphism, but interactions between covariates are
198 less likely for the other pairs.

199 *Interpretability of the p -values.* For each feature, patients are aligned on a common timeline with the individual onset
200 age and pace of atrophy. One can, for instance, observe that for the inferior temporal gyrus, cortical thinning occurs on
201 average 1.5 years earlier for each copy of the ϵ 4 allele, and on average 23% faster for women, after correcting for the
202 other covariates. However these multiple timelines are learned independently and cannot be compared directly in order to
203 exhibit the regions that are mostly affected by a covariate, as it may not be statistically significant. Resorting to statistical
204 testing, using t-tests under the null hypothesis that the regression coefficient is 0, allows to circumvent this issue as it
205 normalizes all the effect sizes by the natural temporal scale associated with the region. Besides, for a fixed sample size,
206 p -values are monotonically related to effect sizes, so lower corrected p -values can be interpreted as indicative of a bigger
207 impact of the covariate, and allow comparison across brain regions and covariates.

208

209 We provide a map of cortical regions and a list of sub-cortical volumes that display significant differences when
210 stratified for sex or APOE- ϵ 4 status, regarding onset age and pace of atrophy, for AD, amyloid positive MCI and healthy
211 aging. Corrected p -values higher than .05 are discarded and the remaining p -values are presented in logarithmic scale
212 (base 10) for cortical thinning maps.

213 3. Results

214 Scales of log p -values vary between each plot and should be taken into account to evaluate the strength of the consid-
215 ered risk factor. For visualization purposes, cortical thinning maps are presented by cohort (AD in Fig. 2, control cohort
216 in Fig. 3 and MCI in Fig. 4) while all results for subcortical volumes are compiled in Table. 2.




Figure 2: Cortical thinning over the course of AD progression. Legend bars shows negative $\log p$ -values. It should be noted that blue values indicate that the considered covariate (female sex or APOE- $\epsilon 4$ genotype) is a protective factor for onset age but a risk factor for pace of atrophy, since higher onset age is better but higher progression pace is worse.

217 *Impact of sex on cortical thinning for AD progression.* Almost all regions of the cortex display a significantly higher
 218 progression pace for female patients, with the exception of the motor cortex, sensory areas and inferior frontal lobe.
 219 Regions that are most accelerated in females are the entire temporal lobe, the middle and superior frontal lobe, the entire
 220 occipital lobe and the anterior and medial parietal lobe. Onset ages are, on the other hand, more homogeneous across
 221 sexes. The motor cortex, the cingulate gyrus and the medial parietal lobe display an earlier onset for men, while the
 222 inferior temporal lobe and inferior frontal lobe display an earlier onset age for female patients. All other regions do not
 223 allow to reject the null hypothesis.

224 *Impact of APOE- $\epsilon 4$ genotype on cortical thinning for AD progression.* Almost all regions of the cortex also display a
 225 significantly higher progression pace for APOE- $\epsilon 4$ carriers. The most affected regions are located roughly in the same
 226 areas as for the impact of sex, but with different regions of highest intensity, and an overall lower effect. The temporal
 227 lobe, the parietal lobe and the frontal lobe also display an earlier onset for APOE- $\epsilon 4$ carriers. The region that presents the
 228 most advanced onset for $\epsilon 4$ carriers is the hippocampal gyrus.

229 *Impact of sex on cortical thinning for healthy aging.* Contrary to what was seen in AD progression, the sexual dimorphism
 230 for healthy aging manifests mainly through a significantly earlier onset age for male subjects, especially in the parietal
 231 and frontal lobes. Only the inferior temporal lobe and subcallosal gyrus display a slightly earlier onset for women. On the
 232 other hand, progression paces are similar across sexes except for the cingulate gyrus that is much accelerated in female
 233 patients, while a few regions of the parietal lobe display a higher pace of atrophy for male patients.




Figure 3: Cortical thinning over the course of cognitively normal aging. Associations with APOE- $\epsilon 4$ status are not displayed as they are not significant.

234 *Impact of APOE- $\epsilon 4$ genotype on cortical thinning for healthy aging.* In order to assess the impact of the APOE- $\epsilon 4$
 235 genotype on cognitively normal aging, we also stratified regarding this factor. Interestingly, the $\epsilon 4$ allele carriers do not
 236 display significantly different patterns for cortical thinning across healthy aging, which leads to believe that APOE- $\epsilon 4$ by
 237 itself does not cause the accelerated atrophy of the brain but only serves as one cog of the unraveling of AD. It should be
 238 noted however that the small amount of $\epsilon 4$ carriers in the healthy cohort can bias this result.




Figure 4: Cortical thinning over the course of MCI patients' aging.

239 *Influence of both covariates for patients with MCI.* The progression paces show little significant correlation with both
 240 covariates, however, for onset age the correlations with sex are similar to those displayed for healthy aging while the
 241 correlations with APOE- ϵ 4 status are similar to those displayed for AD progression, although of a weaker effect.

242 *Correlations with the patterns of atrophy for subcortical structures.* For healthy aging, male sex correlates with an earlier
 243 onset age for most regions with no significant differences in pace of atrophy, while no significant correlation is found for
 244 APOE- ϵ 4 genotype. For the AD cohort on the other hand, female sex correlates with an earlier onset for most regions, and
 245 higher paces of the hippocampi and bilateral amygdalas while APOE- ϵ 4 genotype correlates with earlier onset and higher
 246 pace for the hippocampi and bilateral amygdalas. We reach the same conclusion regarding the MCI cohort as for cortical
 247 thinning : sex correlates with atrophy in a similar fashion to the healthy cohort, while APOE- ϵ 4 genotype correlates in a
 248 similar fashion to the AD cohort. Regions without significant correlations are not displayed.

		Correlations with sex			Correlations with APOE- ϵ 4		
		p_{val} CN	p_{val} MCI	p_{val} AD	p_{val} CN	p_{val} MCI	p_{val} AD
Amygdala (L)	Onset	-	-	8.1e-03	-	4.9e-03	1.9e-07
	Pace	-	-	1.2e-06	-	2.2e-03	7.0e-06
Amygdala (R)	Onset	-	-	7.4e-05	-	3.2e-02	1.4e-06
	Pace	-	-	2.3e-05	-	2.5e-05	1.9e-02
Caudate (L)	Onset	5.5e-07	6.7e-04	1.7e-04	-	-	-
	Pace	-	-	-	-	-	-
Caudate (R)	Onset	1.2e-04	1.8e-04	8.3e-04	-	-	-
	Pace	-	-	-	-	-	-
Hippocampus (L)	Onset	4.7e-06	1.2e-02	-	-	3.0e-03	1.5e-07
	Pace	-	-	3.9e-05	-	5.7e-04	1.2e-02
Hippocampus (R)	Onset	1.1e-04	1.2e-02	-	-	2.1e-03	1.1e-09
	Pace	-	-	1.2e-04	-	3.9e-04	2.6e-02
Pallidum (L)	Onset	4.6e-04	6.9e-04	4.9e-02	-	-	-
	Pace	-	-	-	-	-	-
Pallidum (R)	Onset	6.5e-03	1.8e-04	3.1e-05	-	-	-
	Pace	-	-	-	-	-	-
Thalamus (L)	Onset	1.3e-06	7.8e-12	1.5e-07	-	-	-
	Pace	-	1.1e-02	-	-	-	-
Thalamus (R)	Onset	4.1e-06	4.6e-09	5.5e-08	-	-	-
	Pace	-	-	-	-	-	-

Table 2: Significant correlations with subcortical atrophy. For all the significant features, APOE- ϵ 4 genotype correlate with lower onset age and higher pace, and female sex correlates with higher onset age and higher pace, although correlations with pace are rare and only present in AD and MCI cohorts.

249 *Differences between left and right hemisphere.* For AD progression, the left hemisphere displays more regions that dif-
 250 fer significantly for both sex and APOE- ϵ 4 stratification, but the associated t-values do not significantly differ between
 251 hemispheres. This confirms that atrophic patterns are asymmetric but not completely lateralized [76].

252 *Impact of education level.* Fig. 5 illustrates the impact of education level on cortical thinning patterns, after accounting
 253 for sex and APOE- ϵ 4 status. Correlations are only found in the healthy cohort, and higher education level correlates
 254 with higher onset age for the postcentral gyrus, the medial parietal and medial occipital lobes, as well as the left superior
 255 temporal lobe, and lower pace of atrophy for parts of the frontal and occipital lobes. No significant correlation is found
 256 for the AD cohort, in line with former studies [77]. For subcortical volumes, only the hippocampal atrophy is delayed for
 257 more educated healthy patients, and no significant correlation is found for AD patients. One hypothesis is that education
 258 level is not, in itself, helping delay the atrophy for healthy controls, but acts as a proxy of lifestyle healthiness, which
 259 influences metabolic pathways and brain atrophy. In AD cohort, that small preserving effect is likely to be cancelled by
 260 the influence of other covariates that cause massive atrophy.




Figure 5: Correlation between education level and cortical thinning dynamics for CN patients. Correlations observed for the AD patients are not significant and thus not displayed.

261 *Validation on gray matter density maps from ADNI.* Despite the strong sexual dimorphism in regional gray/white matter
 262 ratios, we recover most results from the main analysis. For AD patients, the same regions display a strong dimorphism :
 263 almost all of the temporal lobe, frontal lobe and occipital lobe display a much stronger atrophic pace for women, while the
 264 postcentral gyrus displays an earlier onset for men. APOE- $\epsilon 4$ allele also correlates with a faster pace and earlier onset in
 265 the medial temporal and parietal lobes, as well as in the temporal lobe and parts of the frontal lobe. For CN patients, we
 266 recover the absence of association with APOE genotype, while men display a much earlier onset for almost all regions
 267 (with emphasis on the parietal lobe and postcentral gyrus), while a few isolated regions of the frontal and temporal lobe
 268 display an faster pace of decline for men. The conclusions regarding the MCI cohort and the impact of education level
 269 are also confirmed. The differences with the main analysis are thus only a matter of a few isolated regions and of the
 270 order of magnitude of the statistical associations. We provide the association figures for cortical thinning and the tables
 271 for subcortical structures in supplementary materials.

272 *Major takeaways.* Our study allows to isolate the contributions from sex, APOE status and education level on both onset
 273 age and pace of atrophy for each region of the cortex and brain, while accounting for the other covariates. We find that :

- 274 • Sex is as important a risk factor as APOE- $\epsilon 4$ genotype for cortical thinning and brain atrophy for AD patients, as
 275 both stratifications yield effect sizes that are not significantly different.
- 276 • Female AD patients decline much faster than male patients, however, the onset of the atrophy is still earlier for male
 277 patients, in line with the healthy aging patterns. This suggests that the disease strikes female patients with much
 278 more intensity, but do not present an earlier onset. This point is revealed by the use of longitudinal studies and has
 279 important implications for practitioners for the follow-up of patients.
- 280 • Education level seems to be a protective factor for healthy patients but is not significant in AD progression.
- 281 • For the MCI cohort, the influence of sex is similar to that of the healthy cohort, while the effect of APOE- $\epsilon 4$
 282 genotype is similar to that of the AD cohort, although of an overall weaker effect.

283 4. Discussion

284 Several limitations and design choices need to be acknowledged in order to put results in perspective.

285 *Clinical characterization of diagnosis in ADNI.* For the control cohort, we used the CN patients in ADNI, because it
 286 allows a fair comparison between AD progression and cognitively normal aging, without acquisition biases. Since ADNI
 287 is not an epidemiological study on healthy aging, the cognitively normal patients may not represent accurately the general

288 population because of ADNI's inclusion criteria. For the MCI cohort, it is important to note that MCI is a cognitive status
289 defined by subjective memory complaints and does not always lead to AD as other factors can cause patients to have it.
290 The prevalence of MCI symptoms are found to be between 15 and 20% for patients over 60 years old [78], and roughly 8
291 to 15% of these convert to AD each year [79]. In order to make the cohort less heterogeneous, we decided to only keep
292 amyloid positive patients in order to interpret this cohort as describing AD pathogenesis. [80] assert that the recruited
293 cohorts for CN, MCI and AD patients successfully describe the associated clinical status.

294 *Validation cohort.* Reproducing this study is complicated because of the lack of publicly available longitudinal database
295 of the same scale as ADNI, and the difficulty to fit longitudinal models to pooled databases with varying protocols. Our
296 statistical pipeline requires to split the patients between CN and AD patients, while only keeping patients with more than
297 2 visits with a t1-MRI scan. For instance with those criteria, in the Australian Imaging Biomarkers and Lifestyle Study of
298 Aging (AIBL), often used to validate findings on ADNI, the AD cohort only contains 38 patients with a total 105 visits,
299 and the healthy cohort 128 patients with 431 visits, before the additional stratification by sex or APOE- ϵ 4 genotype.
300 The sample sizes are thus too small to provide enough statistical power to reproduce the regional map of significant
301 correlations.

302 *Impact of the chosen atlas.* It must be taken into account that the choice of different atlas might yield different results. One
303 anatomical region that is positively associated with a covariate can span many ROIs or on the other hand be split between
304 ROIs and prevent the detection of the true underlying association. On the other hand, our mixed-effect formulation cannot
305 be fitted directly to vertex-wise thickness measurements because the onset age (or horizontal intercept) will not converge
306 for features that display little progression compared to the feature noise.

307 *Regions normalization.* Since subcortical regions' volumes are correlated with the volumes of the skull and brain, it is
308 standard practice to normalize by the intracranial volume in order to allow a fair comparison between subjects. The impact
309 of such normalization is discussed in former studies : in [81, 82, 83] authors suggest that subcortical volumes should be
310 normalized with total intracranial volume, while cortical thicknesses should not, for diagnosis prediction and progression
311 models. On the other hand, [84] find that cortical thicknesses should be normalized with either intracranial volume or
312 average thickness to help predict the cognitive status of a patient. [65] discuss the effect of normalizing cortical thicknesses
313 to allow a fair comparison between healthy male and female subjects. Allometric scaling is often used to circumvent this
314 issue, but [85] find that allometric and linear scaling yield similar effect sizes and coefficients when evaluating the effect
315 of sex and age on brain measurements.

316 *Interpretability of the onset age.* As opposed to the straightforward pace of atrophy, the onset age needs to be interpreted
317 with caution. It represents the age at which a patient crosses a chosen threshold (chosen to be the average value for
318 the whole cohort). Brain atrophy does not have a well-defined starting point and the notion of onset age is thus to be
319 understood with regard to a reference point in the average progression. For instance, the earlier onset ages for men in the
320 CN cohort can be understood as describing the fact that cortical thicknesses are significantly thinner than for women. Since
321 the difference in onset gets way smaller for the AD cohort, it agrees with former findings that the gap between men and
322 women closes as neurodegeneration progresses, with a greater pace of decline for women in the late stages of the disease
323 [51, 52].

324 *Clinical implications.* The discrepancies in alteration patterns of the brain between sexes and APOE genotypes reinforce
325 the idea that the disease manifests differently between subpopulation and care should be provided accordingly. Besides,
326 clinical trials that monitor the effect of a drug on neurodegeneration should put an emphasis on both having more repre-
327 sentative demographics after enrolment, and evaluating the impact of drugs in a stratified manner as patients are likely to
328 react differently to the drug depending on both the explored genetic risk factors. It is also interesting to note that most re-
329 gions significantly affected by the considered risk factors are known to be associated with AD (e.g. medial temporal lobe,
330 limbic system, frontal lobe, etc). This work could be interpreted jointly with studies that describe the sexual differences in
331 associations between cortical thickness and cognition such as [52] in order to provide a complete description of the sexual
332 dimorphism of neurodegeneration and its link with AD cognitive symptoms.

333 *Perspectives.* This statistical pipeline can be applied to other modalities of neuroimaging data. For instance, [86] applies
334 the same statistical pipeline to FDG-PET scans instead of structural MRI in order to assess the sexual dimorphism of AD
335 and influence of APOE genotype regarding brain hypometabolism, which complements the study of brain atrophy. Other
336 imaging modalities specific to AD, such as amyloid-PET or tau-PET, are also under investigation within this pipeline. A
337 strong sexual dimorphism for the spreading patterns of pathological protein tangles in the brain would prompt the latest
338 clinical trials, that choose amyloid load as a primary disease outcome, to put great care in evaluating the differentiated
339 results between male and female patients.

340 **5. Conclusion**

341 Structural alterations of the brain happen before the onset of cognitive decline and the collection of MRI-derived
342 features reveals varying patterns of atrophy between subgroups of patients. Female sex, APOE- ϵ 4 genotype and low
343 education level have been identified as the biggest risk factors for cognitive decline, but their impact on early-stage
344 structural alterations is not yet well understood. In this work we described the disentangled effects of these 3 covariates
345 on the onset and pace of regional atrophy and cortical thinning. This reveals that female sex is actually as strong a risk
346 factor for neurodegeneration as APOE- ϵ 4 genotype, and women experience much faster atrophic rates after correcting for
347 the APOE genotype. APOE- ϵ 4 genotype leads to earlier and faster atrophy for most regions of the brain for AD patients
348 but not for healthy patients. Healthy patients with higher education experience slightly delayed atrophy but not patients
349 with neurodegeneration. The results were validated with congruent findings from the same study applied to the regional
350 loss of gray matter density. This work calls for further exploration of the sexual dimorphism of AD regarding structural
351 alterations.

352 **6. Acknowledgments**

353 This work was funded in part by the French government under management of Agence Nationale de la Recherche as
354 part of the "Investissements d'avenir" program, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute), ANR-19-JPW2-
355 000 (E-DADS) and ANR10-IAIHU-06 (IHU ICM), as well as by the European Research council reference ERC-678304
356 and the H2020 programme via grant 826421 (TVB-Cloud). This work already appears online as a preprint with the same
357 title.

358
359 There are no conflicts of interest associated with this publication. As per ADNI protocols, all procedures performed
360 in studies involving human participants were in accordance with the ethical standards of the institutional and/or national
361 research committee and with the 1964 Helsinki declaration and its later amendments. More details can be found at
362 adni.loni.usc.edu. (This article does not contain any studies with human participants performed by any of the authors).

363

References

- [1] Alzheimer's Association *et al.*, "2016 alzheimer's disease facts and figures," *Alzheimer's & Dementia* **12**(4), 459–509 (2016).
- [2] L. E. Hebert, P. A. Scherr, L. A. Beckett, *et al.*, "Age-specific incidence of alzheimer's disease in a community population," *Jama* **273**(17), 1354–1359 (1995).
- [3] L. Hebert, J. Bienias, N. Aggarwal, *et al.*, "Change in risk of alzheimer disease over time," *Neurology* **75**(9), 786–791 (2010).
- [4] R. E. Tanzi, "The genetics of alzheimer disease," *Cold Spring Harbor perspectives in medicine* **2**(10), a006296 (2012).
- [5] A. M. Saunders, W. J. Strittmatter, D. Schmechel, *et al.*, "Association of apolipoprotein e allele 4 with late-onset familial and sporadic alzheimer's disease," *Neurology* **43**(8), 1467–1467 (1993).
- [6] L. A. Farrer, L. A. Cupples, J. L. Haines, *et al.*, "Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease: a meta-analysis," *Jama* **278**(16), 1349–1356 (1997).
- [7] R. W. Mahley and Y. Huang, "Apolipoprotein e sets the stage: response to injury triggers neuropathology," *Neuron* **76**(5), 871–885 (2012).
- [8] K. R. Laws, K. Irvine, and T. M. Gale, "Sex differences in cognitive impairment in alzheimer's disease," *World journal of psychiatry* **6**(1), 54 (2016).
- [9] C. R. Beam, C. Kaneshiro, J. Y. Jang, *et al.*, "Differences between women and men in incidence rates of dementia and alzheimer's disease," *Journal of Alzheimer's Disease* **64**(4), 1077–1083 (2018).
- [10] A. Członkowska, A. Ciesielska, G. Gromadzka, *et al.*, "Gender differences in neurological disease," *Endocrine* **29**(2), 243–256 (2006).
- [11] A. R. Genazzani, N. Pluchino, S. Luisi, *et al.*, "Estrogen, cognition and female ageing," *Human reproduction update* **13**(2), 175–187 (2007).
- [12] E. Sinforiani, A. Citterio, C. Zucchella, *et al.*, "Impact of gender differences on the outcome of alzheimer's disease," *Dementia and geriatric cognitive disorders* **30**(2), 147–154 (2010).
- [13] J. Martinkova, F.-C. Quevenco, H. Karcher, *et al.*, "Proportion of women and reporting of outcomes by sex in clinical trials for alzheimer disease: a systematic review and meta-analysis," *JAMA Network Open* **4**(9), e2124124–e2124124 (2021).
- [14] J. B. Schwartz and S. Weintraub, "Treatment for alzheimer disease—sex and gender effects need to be explicitly analyzed and reported in clinical trials," *JAMA network open* **4**(9), e2124386–e2124386 (2021).
- [15] M. M. Mielke, "Sex and gender differences in alzheimer's disease dementia," *The Psychiatric times* **35**(11), 14 (2018).
- [16] C. M. Roe, C. Xiong, J. P. Miller, *et al.*, "Education and alzheimer disease without dementia: support for the cognitive reserve hypothesis," *Neurology* **68**(3), 223–228 (2007).
- [17] Y. Stern, "Cognitive reserve in ageing and alzheimer's disease," *The Lancet Neurology* **11**(11), 1006–1012 (2012).
- [18] S. Subramaniapillai, S. Rajagopal, J. Snytte, *et al.*, "Sex differences in brain aging among adults with family history of alzheimer's disease and apoe4 genetic risk," *NeuroImage: Clinical* **30**, 102620 (2021).
- [19] D. Mungas, B. Gavett, E. Fletcher, *et al.*, "Education amplifies brain atrophy effect on cognitive decline: implications for cognitive reserve," *Neurobiology of Aging* **68**, 142–150 (2018).
- [20] A. Altmann, L. Tian, V. W. Henderson, *et al.*, "Sex modifies the apoe-related risk of developing alzheimer disease," *Annals of neurology* **75**(4), 563–573 (2014).
- [21] F. Sampedro, E. Vilaplana, M. J. De Leon, *et al.*, "ApoE-by-sex interactions on brain structure and metabolism in healthy elderly controls," *Oncotarget* **6**(29), 26663 (2015).
- [22] S. C. Neu, J. Pa, W. Kukull, *et al.*, "Apolipoprotein e genotype and sex risk factors for alzheimer disease: a meta-analysis," *JAMA neurology* **74**(10), 1178–1189 (2017).

- [23] R. F. Buckley, E. C. Mormino, R. E. Amariglio, *et al.*, “Sex, amyloid, and apoe ϵ 4 and risk of cognitive decline in preclinical alzheimer’s disease: Findings from three well-characterized cohorts,” *Alzheimer’s & Dementia* **14**(9), 1193–1203 (2018).
- [24] M. T. Ferretti, M. F. Iulita, E. Cavedo, *et al.*, “Sex differences in alzheimer disease—the gateway to precision medicine,” *Nature Reviews Neurology* **14**(8), 457–469 (2018).
- [25] K. R. Laws, K. Irvine, and T. M. Gale, “Sex differences in alzheimer’s disease,” *Current opinion in psychiatry* **31**(2), 133–139 (2018).
- [26] C. E. Coffey, J. F. Lucke, J. A. Saxton, *et al.*, “Sex differences in brain aging: a quantitative magnetic resonance imaging study,” *Archives of neurology* **55**(2), 169–179 (1998).
- [27] P. E. Cowell, B. I. Turetsky, R. C. Gur, *et al.*, “Sex differences in aging of the human frontal and temporal lobes,” *Journal of Neuroscience* **14**(8), 4748–4755 (1994).
- [28] A. C. McCarrey, Y. An, M. H. Kitner-Triolo, *et al.*, “Sex differences in cognitive trajectories in clinically normal older adults.,” *Psychology and aging* **31**(2), 166 (2016).
- [29] N. M. Armstrong, Y. An, L. Beason-Held, *et al.*, “Sex differences in brain aging and predictors of neurodegeneration in cognitively healthy older adults,” *Neurobiology of aging* **81**, 146–156 (2019).
- [30] C. R. Jack, H. J. Wiste, S. D. Weigand, *et al.*, “Age, sex, and apoe ϵ 4 effects on memory, brain structure, and β -amyloid across the adult life span,” *JAMA neurology* **72**(5), 511–519 (2015).
- [31] H. Fonteijn, M. Modat, M. Clarkson, *et al.*, “An event-based model for disease progression and its application in familial Alzheimer’s disease and Huntington’s disease,” *NeuroImage* **60**(3), 1880–1889 (2012).
- [32] A. Young, N. Oxtoby, P. Daga, *et al.*, “A data-driven model of biomarker changes in sporadic Alzheimer’s disease,” *Brain* **137**(9), 2564–2577 (2014).
- [33] M. Lorenzi, M. Filippone, G. B. Frisoni, *et al.*, “Probabilistic disease progression modeling to characterize diagnostic uncertainty: application to staging and prediction in alzheimer’s disease,” *NeuroImage* **190**, 56–68 (2019).
- [34] C. Abi Nader, N. Ayache, P. Robert, *et al.*, “Monotonic gaussian process for spatio-temporal disease progression modeling in brain imaging data,” *Neuroimage* **205**, 116266 (2020).
- [35] R. Couronné, M. Louis, and S. Durrleman, “Longitudinal autoencoder for multi-modal disease progression modelling.” preprint (2019).
- [36] B. Sauty and S. Durrleman, “Progression models for imaging data with longitudinal variational auto encoders,” in *MICCAI 2022, International Conference on Medical Image Computing and Computer Assisted Intervention*, (2022).
- [37] K. Ito, B. Corrigan, Q. Zhao, *et al.*, “Disease progression model for cognitive deterioration from alzheimer’s disease neuroimaging initiative database,” *Alzheimer’s & Dementia* **7**(2), 151–160 (2011).
- [38] M. N. Samtani, M. Farnum, V. Lobanov, *et al.*, “An improved model for disease progression in patients from the alzheimer’s disease neuroimaging initiative,” *The Journal of Clinical Pharmacology* **52**(5), 629–644 (2012).
- [39] M. Bilgel, Y. An, A. Lang, *et al.*, “Trajectories of alzheimer disease-related cognitive measures in a longitudinal sample,” *Alzheimer’s & Dementia* **10**(6), 735–742 (2014).
- [40] B. Jedynak, A. Lang, B. Liu, *et al.*, “A computational neurodegenerative disease progression score: method and results with the Alzheimer’s disease neuroimaging initiative cohort,” *Neuroimage* **63**(3), 1478–1486 (2012).
- [41] J.-B. Schiratti, S. Allasonniere, O. Colliot, *et al.*, “Learning spatiotemporal trajectories from manifold-valued longitudinal data,” in *Neural Information Processing Systems*, (28) (2015).
- [42] I. Koval, J.-B. Schiratti, A. Routier, *et al.*, “Statistical learning of spatiotemporal patterns from longitudinal manifold-valued networks,” in *International Conference on MICCAI*, 451–459, Springer (2017).
- [43] L. L. Raket, “Statistical disease progression modeling in Alzheimer disease,” *Frontiers in big Data* **3** (2020).
- [44] J. L. Bernal-Rusiel, D. N. Greve, M. Reuter, *et al.*, “Statistical analysis of longitudinal neuroimage data with linear mixed effects models,” *Neuroimage* **66**, 249–260 (2013).
- [45] J. L. Bernal-Rusiel, M. Reuter, D. N. Greve, *et al.*, “Spatiotemporal linear mixed effects modeling for the mass-univariate analysis of longitudinal neuroimage data,” *Neuroimage* **81**, 358–370 (2013).

- [46] M. R. Sabuncu, J. L. Bernal-Rusiel, M. Reuter, *et al.*, “Event time analysis of longitudinal neuroimage data,” *NeuroImage* **97**, 9–18 (2014).
- [47] S. L. Risacher, L. Shen, J. D. West, *et al.*, “Longitudinal mri atrophy biomarkers: relationship to conversion in the adni cohort,” *Neurobiology of aging* **31**(8), 1401–1418 (2010).
- [48] N. J. Tustison, A. J. Holbrook, B. B. Avants, *et al.*, “Longitudinal mapping of cortical thickness measurements: An alzheimer’s disease neuroimaging initiative-based evaluation study,” *Journal of Alzheimer’s Disease* **71**(1), 165–183 (2019).
- [49] Y. Li, L. Zhang, A. Bozoki, *et al.*, “Early prediction of alzheimer’s disease using longitudinal volumetric mri data from adni,” *Health Services and Outcomes Research Methodology* **20**(1), 13–39 (2020).
- [50] X. Hua, D. P. Hibar, S. Lee, *et al.*, “Sex and age differences in atrophic rates: an adni study with n= 1368 mri scans,” *Neurobiology of aging* **31**(8), 1463–1480 (2010).
- [51] O. Sangha, D. Ma, K. Popuri, *et al.*, “Structural volume and cortical thickness differences between males and females in cognitively normal, cognitively impaired and alzheimer’s dementia population,” *Neurobiology of Aging* **106**, 1–11 (2021).
- [52] F. Cieri, X. Zhuang, D. Cordes, *et al.*, “Relationship of sex differences in cortical thickness and memory among cognitively healthy subjects and individuals with mild cognitive impairment and alzheimer disease,” *Alzheimer’s research & therapy* **14**(1), 1–12 (2022).
- [53] L. Gutiérrez-Galve, M. Lehmann, N. Z. Hobbs, *et al.*, “Patterns of cortical thickness according to apoe genotype in alzheimer’s disease,” *Dementia and geriatric cognitive disorders* **28**(5), 461–470 (2009).
- [54] S. Abushakra, A. P. Porsteinsson, M. Sabbagh, *et al.*, “ApoE $\epsilon 4/\epsilon 4$ homozygotes with early alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline,” *Alzheimer’s & Dementia: Translational Research & Clinical Interventions* **6**(1), e12117 (2020).
- [55] Y. Liu, J.-T. Yu, H.-F. Wang, *et al.*, “ApoE genotype and neuroimaging markers of alzheimer’s disease: systematic review and meta-analysis,” *Journal of Neurology, Neurosurgery & Psychiatry* **86**(2), 127–134 (2015).
- [56] B. Li, J. Shi, B. A. Gutman, *et al.*, “Influence of apoe genotype on hippocampal atrophy over time-an n= 1925 surface-based adni study,” *PloS one* **11**(4), e0152901 (2016).
- [57] J. Kim, S. Park, H. Yoo, *et al.*, “The impact of apoe 4 in alzheimer’s disease differs according to age,” *Journal of Alzheimer’s Disease* **61**(4), 1377–1385 (2018).
- [58] O. Hansson, J. Seibyl, E. Stomrud, *et al.*, “Csf biomarkers of alzheimer’s disease concord with amyloid- β pet and predict clinical progression: a study of fully automated immunoassays in biofinder and adni cohorts,” *Alzheimer’s & dementia* **14**(11), 1470–1481 (2018).
- [59] A. Routier, N. Burgos, M. Díaz, *et al.*, “Clinica: An open-source software platform for reproducible clinical neuroscience studies,” *Frontiers in Neuroinformatics* **15** (2021).
- [60] B. Fischl, “Freesurfer,” *NeuroImage* **62**(2), 774–781 (2012).
- [61] C. Destrieux, B. Fischl, A. Dale, *et al.*, “Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature,” *NeuroImage* **53**(1), 1–15 (2010).
- [62] M. Lehmann, A. Douiri, L. G. Kim, *et al.*, “Atrophy patterns in alzheimer’s disease and semantic dementia: a comparison of freesurfer and manual volumetric measurements,” *NeuroImage* **49**(3), 2264–2274 (2010).
- [63] L. Clerx, H. Gronenschild, C. Echavarri, *et al.*, “Can freesurfer compete with manual volumetric measurements in alzheimer’s disease?,” *Current Alzheimer Research* **12**(4), 358–367 (2015).
- [64] N. Tzourio-Mazoyer, B. Landeau, D. Papathanassiou, *et al.*, “Automated anatomical labeling of activations in spm using a macroscopic anatomical parcellation of the mni mri single-subject brain,” *NeuroImage* **15**(1), 273–289 (2002).
- [65] E. Luders, K. L. Narr, P. M. Thompson, *et al.*, “Gender effects on cortical thickness and the influence of scaling,” *Human brain mapping* **27**(4), 314–324 (2006).
- [66] X. Chen, P. S. Sachdev, W. Wen, *et al.*, “Sex differences in regional gray matter in healthy individuals aged 44–48 years: a voxel-based morphometric study,” *NeuroImage* **36**(3), 691–699 (2007).

- [67] M. Lotze, M. Domin, F. H. Gerlach, *et al.*, “Novel findings from 2,838 adult brains on sex differences in gray matter brain volume,” *Scientific reports* **9**(1), 1–7 (2019).
- [68] X. Han, J. Jovicich, D. Salat, *et al.*, “Reliability of mri-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer,” *Neuroimage* **32**(1), 180–194 (2006).
- [69] J.-B. Schiratti, S. Allassonniere, O. Colliot, *et al.*, “Learning spatiotemporal trajectories from manifold-valued longitudinal data,” in *Neural Information Processing Systems, Advances in Neural Information Processing Systems*, (Montréal, Canada) (2015).
- [70] I. Koval, J.-B. Schiratti, A. Routier, *et al.*, “Statistical learning of spatiotemporal patterns from longitudinal manifold-valued networks,” in *Medical Image Computing and Computer Assisted Intervention MICCAI 2017*, M. Descoteaux, L. Maier-Hein, A. Franz, *et al.*, Eds., 451–459, Springer International Publishing, (Cham) (2017).
- [71] E. Kuhn and M. Lavielle, “Coupling a stochastic approximation version of em with an mcmc procedure,” *ESAIM: Probability and Statistics* **8**, 115–131 (2004).
- [72] S. Allassonnière, E. Kuhn, and A. Trouvé, “Construction of bayesian deformable models via a stochastic approximation algorithm: a convergence study,” *Bernoulli* **16**(3), 641–678 (2010).
- [73] S. Gruffaz, P.-E. Poulet, E. Maheux, *et al.*, “Learning riemannian metric for disease progression modeling,” *Advances in Neural Information Processing Systems* **34** (2021).
- [74] B. Sauty and S. Durrleman, “Riemannian metric learning for progression modeling of longitudinal datasets,” in *ISBI 2022-International Symposium on Biomedical Imaging*, (2022).
- [75] Y. Benjamini and D. Yekutieli, “False discovery rate–adjusted multiple confidence intervals for selected parameters,” *Journal of the American Statistical Association* **100**(469), 71–81 (2005).
- [76] S. Derflinger, C. Sorg, C. Gaser, *et al.*, “Grey-matter atrophy in alzheimer’s disease is asymmetric but not lateralized,” *Journal of Alzheimer’s Disease* **25**(2), 347–357 (2011).
- [77] I. Koval, A. Bône, M. Louis, *et al.*, “Ad course map charts alzheimer’s disease progression,” *Scientific Reports* **11**(1), 1–16 (2021).
- [78] S. Gauthier, B. Reisberg, M. Zaudig, *et al.*, “Mild cognitive impairment,” *The lancet* **367**(9518), 1262–1270 (2006).
- [79] R. C. Petersen, “Mild cognitive impairment,” *CONTINUUM: Lifelong Learning in Neurology* **22**(2 Dementia), 404 (2016).
- [80] R. C. Petersen, P. Aisen, L. A. Beckett, *et al.*, “Alzheimer’s disease neuroimaging initiative (adni): clinical characterization,” *Neurology* **74**(3), 201–209 (2010).
- [81] J. L. Whitwell, W. R. Crum, H. C. Watt, *et al.*, “Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative mr imaging,” *American journal of neuroradiology* **22**(8), 1483–1489 (2001).
- [82] E. Westman, C. Aguilar, J.-S. Muehlboeck, *et al.*, “Regional magnetic resonance imaging measures for multivariate analysis in alzheimer’s disease and mild cognitive impairment,” *Brain topography* **26**(1), 9–23 (2013).
- [83] O. Voevodskaya, A. Simmons, R. Nordenskjöld, *et al.*, “The effects of intracranial volume adjustment approaches on multiple regional mri volumes in healthy aging and alzheimer’s disease,” *Frontiers in aging neuroscience* **6**, 264 (2014).
- [84] Q. Zhou, M. Goryawala, M. Cabrerizo, *et al.*, “Significance of normalization on anatomical mri measures in predicting alzheimer’s disease,” *The Scientific World Journal* **2014** (2014).
- [85] C. M. Williams, H. Peyre, R. Toro, *et al.*, “Neuroanatomical norms in the uk biobank: The impact of allometric scaling, sex, and age,” *Human Brain Mapping* **42**(14), 4623–4642 (2021).
- [86] B. Sauty and S. Durrleman, “Impact of sex and apoe- ϵ 4 genotype on regional brain metabolism in alzheimer’s disease,” in *2023 IEEE 20th International Symposium on Biomedical Imaging (ISBI)*, (2023).